Stocks Health care COR
NYSE · Health careCencora, Inc. (COR)
Cencora, Inc. brought in $332.8B of revenue over the twelve months to June 30, 2026, up 5.1% from a year earlier. Net income was $2.6B, a net margin of 0.8%. Operating cash flow minus capital spending left $3.2B of free cash flow in fiscal 2025. At June 30, 2026 it held $2.8B in cash against $11.7B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
Key facts about Cencora, Inc.
- Net worth
- Cencora, Inc. has a market value (market cap) of $65.9B at the latest share price, and shareholders' equity of $3.1B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $321.3B (+9.3% year on year), with net income of $1.6B. Over the 12 months to June 30, 2026: revenue $332.8B, net income $2.6B.
- Cash flow
- In fiscal 2025 operations brought in $3.9B of cash; after $668M of capital spending, free cash flow was $3.2B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cencora, Inc.'s next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Cencora, Inc. declared dividends of $2.20 per share in fiscal 2025, a yield of 0.64% at the current price.
What Cencora, Inc. does
Cencora distributes pharmaceutical products and provides healthcare services to pharmacies, hospitals, clinics, and veterinary practices. It purchases brand-name and generic medications directly from manufacturers, manages logistics and supply chains, and supplies pharmacies and medical facilities worldwide. Its shares trade on NYSE under the ticker COR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $321.3B | $1.6B | $7.96 | $3.2B |
| 2024 | $294B | $1.5B | $7.53 | $3B |
| 2023 | $262.2B | $1.7B | $8.53 | $3.5B |
| 2022 | $238.6B | $1.7B | $8.04 | $2.2B |
| 2021 | $214B | $1.5B | $7.39 | $2.2B |
| 2020 | $189.9B | -$3.4B | -$16.65 | $1.8B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where COR ranks in Health care
Dividends
Cencora, Inc. declared $2.20 per share in fiscal 2025. At the current price that is a yield of 0.64%. It paid out $437.1M in cash dividends, 28% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $2.20 | $437.1M | 28% |
| 2024 | $2.04 | $416.2M | 28% |
| 2023 | $1.94 | $398.8M | 23% |
| 2022 | $1.84 | $391.7M | 23% |
| 2021 | $1.76 | $366.6M | 24% |
| 2020 | $1.66 | $343.6M | n/a |
Latest SEC filings
What Cencora, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- October 21, 2026
- September 25, 2026Executive or director change8-KCencora appointed Robert E. Sanchez to its Board of Directors effective October 1, 2026.
- August 14, 2026
- August 12, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5.1% to $84.8B versus the same quarter last year; diluted EPS $3.94 versus $3.52.
- August 5, 2026
- August 5, 2026
- June 18, 2026
What is COR worth? A DCF from its reported cash flow
Insider trades
What the people running Cencora, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $5M worth of shares in the last 90 days and bought none on the open market. 19% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Krikorian LazarusSVP & Chief Accounting Officer | Soldpre-planned (10b5-1) | 986 | $326.3K |
| October 30, 2026 | Cooper EllenDirector | Received as pay | 91 | $30.1K |
| October 30, 2026 | Verma PawanEVP, Chief Data & Info Officer | Exercised options | 8,538 | - |
| October 30, 2026 | Verma PawanEVP, Chief Data & Info Officer | Shares withheld for tax | 4,254 | $1.4M |
| October 30, 2026 | Nally Dennis MDirector | Received as pay | 106 | $35.1K |
| October 30, 2026 | Tyler Lauren MDirector | Received as pay | 91 | $30.1K |
| October 1, 2026 | Sanchez Robert EDirector | Received as pay | 275 | - |
| October 1, 2026 | Krikorian LazarusSVP & Chief Accounting Officer | Soldpre-planned (10b5-1) | 986 | $298.9K |
Who owns COR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.3% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,344 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 18,213,783 | -1,729,854 |
| Vanguard Capital Management LLC | 12,378,943 | +65,484 |
| Vanguard Portfolio Management LLC | 9,611,756 | +21,342 |
| State Street Corp | 9,273,983 | +83,432 |
| Jpmorgan Chase & Co | 5,943,657 | +1,058,179 |
| Geode Capital Management, LLC | 5,454,888 | -111,156 |
| Boston Partners | 4,868,782 | +385,965 |
| Wellington Management Group Llp | 4,559,761 | +11,149 |
| Fmr LLC | 4,122,371 | -2,563,898 |
| Morgan Stanley | 4,086,271 | -445,641 |
| Bank of America Corp | 3,733,921 | -404,467 |
| Norges Bank | 2,473,825 | new |
| Goldman Sachs Group Inc | 2,274,148 | +61,260 |
| Amundi | 2,229,326 | +676,066 |
| Northern Trust Corp | 2,158,939 | -23,736 |
| Invesco Ltd. | 2,021,234 | -1,966,502 |
| Capital Research Global Investors | 1,979,942 | +20,292 |
| Carmignac Gestion | 1,747,363 | +646,112 |
| Mitsubishi UFJ Asset Management Co., Ltd. | 1,709,563 | +349,835 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,708,377 | +91,814 |
Insiders
17 insiders reported holding 374,769 shares in total, about $129.4M at the last price.
| Holder | Shares |
|---|---|
| Cleary James FChief Financial Officer | 160,357 |
| Mauch Robert P.President & CEO, Director | 65,393 |
| Durcan Dermot MarkDirector | 31,767 |
| Battaglia SilvanaExecutive Vice President | 23,624 |
| Campbell Elizabeth SExecutive Vice President | 19,455 |
| Greenberg Lon RDirector | 17,128 |
| Krikorian LazarusSVP & Chief Accounting Officer | 14,197 |
| Nally Dennis MDirector | 13,294 |
| Verma PawanEVP, Chief Data & Info Officer | 9,432 |
| Tyler Lauren MDirector | 4,547 |
Questions about COR
What does Cencora, Inc. do?
Cencora distributes pharmaceutical products and provides healthcare services to pharmacies, hospitals, clinics, and veterinary practices. It purchases brand-name and generic medications directly from manufacturers, manages logistics and supply chains, and supplies pharmacies and medical facilities worldwide. Its shares trade on NYSE under the ticker COR.
What is Cencora, Inc.'s net worth?
Cencora, Inc. has a market value (market cap) of $65.9B at the latest share price, and shareholders' equity of $3.1B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cencora, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $2.6B on revenue of $332.8B, a net margin of 0.8%.
How much revenue does Cencora, Inc. make?
Over the twelve months to June 30, 2026 Cencora, Inc. reported revenue of $332.8B. That is 5.1% more than a year earlier.
When did Cencora, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from November 4, 2026.
When is Cencora, Inc.'s next earnings report?
Cencora, Inc.'s next report is expected around February 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Does Cencora, Inc. pay a dividend?
Yes. Cencora, Inc. declared dividends of $2.20 per share in fiscal 2025, a yield of 0.64% at the current price.
Similar companies
Compare COR with
Follow COR
Get an email when Cencora, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cencora, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.